Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... Pickleball Program Boosts Health and ...

A survey of the nation's oncologists showed that professional burnout has reached a new high (59% vs 45% in 2013), and fewer ...

The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

San Diego, USA-based Turnstone Biologics yesterday announced that it has completed an assessment of its business and ...

A spokesperson for the Cholangiocarcinoma Foundation writes that experimental cancer trials saved her life and could save the ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a ...

Lunit offers free AI biomarker services to SITC researchers for immuno-oncology studies Global researchers gain access to ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.